HHS opposes pediatric legislation
This article was originally published in The Gray Sheet
HHS Secretary Michael Leavitt is expressing "major concerns" about pediatric device language in the FDA Revitalization Act (S 1082), which cleared the Senate Health, Education, Labor and Pensions Committee April 18. In an April 17 letter to HELP Chairman Sen. Edward Kennedy, D-Mass., Leavitt writes that HHS opposes provisions that sanction government funding of research run by private consortia and allow firms to profit from devices approved under a humanitarian device exemption. The pediatric device section of the bill is intended to offer incentives to manufacturers to develop devices for children and adolescents (1"The Gray Sheet" April 2, 2007, p. 25). Amendments could be added to the legislation, which also includes provisions reauthorizing medical device and pharmaceutical user fee programs, before the full Senate votes on the measure...
You may also be interested in...
Sen. Christopher Dodd, D-Conn., is pushing for quick action on legislation to provide incentives for the development of pediatric medical devices
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.